Press Release Archive
-
New Phase 2 Data Show Stelara® (Ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year
-
Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.
-
Johnson & Johnson Announces Promising, Early-Stage Results for Tetravalent Mosaic-based HIV Preventive Vaccine Regimen
-
Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
-
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018
-
Johnson & Johnson Reports 2018 Third-Quarter Results:
-
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
-
JANSSEN TO HIGHLIGHT DATA FROM BROAD RHEUMATOLOGY PORTFOLIO AT THE 2018 ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY
-
NEW PHASE 3 DATA SHOW SINGLE DOSE OF STELARA® (USTEKINUMAB) INDUCES CLINICAL REMISSION AND RESPONSE IN ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
-
Janssen Submits European Marketing Authorisation Application for Esketamine Nasal Spray for Treatment-Resistant Depression